article thumbnail

As Viatris seeks growth in eye care, its Ocuphire-partnered dilation drop Ryzumvi wins FDA nod

Fierce Pharma

The FDA on Wednesday approved Viatris and Ocuphire’s Ryzumvi, also known as phentolamine ophthalmic solution, to treat pharmacologically-induced mydriasis, or dilation of the pupils. Viatris just notched a win on its quest to reach $1 billion in eye care sales by 2028. | The partners plan to make Ryzumvi available in the U.S.

article thumbnail

Viatris, Ocuphire Pharma Receive FDA Approval on Ryzumvi

PharmExec

Eye drop treatment indicated for pharmacologically induced mydriasis.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Abliva’s NV354 receives ODD from US FDA

Pharma Leaders

Sweden-based Abliva has announced that its drug candidate NV354 has been received orphan drug designation (ODD) from the US FDA Office of Orphan Products Development to treat mitochondrial disease. FDA is a validation of the quality of the NV354 pre-clinical program and another important milestone for Abliva.

FDA 52
article thumbnail

Pharmaceutical Sales Training: Mastering the Art of Modern Pharma Sales

Contrarian Sales Techniques

It's the secret sauce to thriving in the pharma industry. From cutting-edge training techniques that break the mold, to the latest industry trends making waves, and the career development hacks every pharma rep should know – we've got it all covered. Welcome to the world where sales training isn't just a formality.

article thumbnail

Novartis drops presbyopia drug acquired with Encore Vision

pharmaphorum

At the time of the Encore Vision takeover, there were pharmacological therapies for presbyopia, but that changed last year when AbbVie secured FDA approval for Vuity , a once-daily eyedrop formulation of pilocarpine, as the first drug for the common eye condition. Image by Oscar Aznar from Pixabay .

article thumbnail

Astellas loses bid to block Lexiscan generics in US

pharmaphorum

It looks like Astellas has been unsuccessful in its attempt to block Pfizer’s generic medicines unit Hospira from launching a copycat version of big-selling pharmacologic stress agent Lexiscan in the US. AmphaStar and Glenmark Pharma also claimed FDA approval for versions of the drug earlier this year.

article thumbnail

Astellas facing generics to big-selling Lexiscan product in US

pharmaphorum

Astellas has won a reprieve in its attempt to stop Pfizer’s generic medicines unit Hospira launching a copycat version of its pharmacologic stress agent Lexiscan in the US – but only for a couple of weeks. AmphaStar and Glenmark Pharma also claimed FDA approval for versions of the drug earlier this year.